Hosted on MSN7mon
FDA Approves Novel Nebulized Therapy for COPDThe FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment ... From baseline to week 12, average FEV 1 area under the curve at 0 to 12 hours improved by 87 mL and 94 mL versus ...
“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine ... in the form of ADSs, under its “at the market” equity offering program ...
“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine ... in the form of ADSs, under its “at the market” equity offering program ...
LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback